N-803 is also currently being evaluated in combination with other immunotherapeutic strategies, such as chimeric antigen receptor (CAR)-T cell therapy (NCT04847466) and Anti-PD-L1/TGF-beta ‘Trap’ with Bintrafusp alfa (M7824) plus TriAd Vaccine (ETBX-011, ETBX-051, and ETBX-061) (NCT04247282, a Sequential Window of Opportunity Trial), in HNSCC. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.